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A 4 y old boy of Korean ancestry had xeroderma pig-
mentosum (XP) with sun sensitivity, multiple cutaneous
neoplasms, and inability to speak. Neurologic examina-
tion revealed hyperactivity and autistic features without
typical XP neurologic abnormalities. Cultured skin
fibroblasts (XP22BE) showed decreased post-UV survival,
reduced post-UV plasmid host cell reactivation and
defective DNA repair (16% of normal unscheduled DNA
synthesis in intact cells and undetectable excision repair
in a cell free extract). In vitro and in vivo complementation
assigned XP22BE to XP group C (XPC) and a markedly
reduced level of XPC mRNA was found. Two XPC
cDNA bands were identified. One band had a deletion
of 161 bases comprising the entire exon 9, which resulted
in premature termination of the mutant XPC mRNA.
Xeroderma pigmentosum (XP) is a rare autosomal recess-ive disease associated with extreme sensitivity to ultravi-olet radiation (UV), resulting in a high incidence ofskin cancers (µ1000 times that of the general popula-tion) and neurologic disorders in about 20% of the
patients (Kraemer et al, 1987, 1994). All seven different DNA repair
genes (XPA-G) involved in XP have recently been identified (reviewed
in Bootsma et al, 1998). XP complementation group C (XPC) is the
most prevalent form among North Americans and Europeans. XPC
patients exhibit elevated frequency of skin cancers but rarely have the
neurologic abnormalities, which are common in the more severe forms
of XP (XPA, XPB, XPD, and XPG). The molecular defects in the
XPC gene that account for the repair deficiency and elevated skin
cancers have been analyzed in only five XPC patients (Legerski and
Peterson, 1992; Li et al, 1993), and splice site mutations in the XPC
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The larger band also had the same deletion of exon 9
but, in addition, had an insertion of 155 bases in its place
(exon 9a), resulting in an in-frame XPC mRNA. Genomic
DNA analysis revealed a T→G mutation at the splice
donor site of XPC exon 9, which markedly reduced its
information content. The 155 base pair XPC exon 9a
insertion was located in intron 9 and was flanked by
strong splice donor and acceptor sequences. Analysis of
the patient’s blood showed persistently low levels of
glycine (68 mM; NL, 125–318 mM). Normal glycine levels
were maintained with oral glycine supplements and his
hyperactivity diminished. These data provide evidence
of an association of an XPC splice site mutation with
autistic neurologic features and hypoglycinemia. Key
words: alternative splicing/amino acid metabolism/DNA repair/
skin cancer. J Invest Dermatol 111:791–796, 1998
gene have not previously been reported. Here we describe a very
young (4 y old) XPC patient (XP22BE) with multiple skin cancers,
including melanoma, unusual neurologic abnormalities (namely, normal
hearing and normal reflexes with hyperactivity and autistic features), a
splice site mutation, and hypoglycinemia.
MATERIALS AND METHODS
Cell lines and culture conditions XP22BE (GM013817), XP21BE
(GM09942) XPC and normal (AG10107) lymphoblastoid cells, and XP21RO
(GM00709) XPC and normal (GM02987C) fibroblasts were obtained from the
Human Genetic Mutant Cell Repository (Camden, NJ). The patient was
studied under a protocol approved by the NIH Institutional Review Board
(91-AR-0161). XP22BE fibroblasts were established from a skin biopsy by
H.L. Levy. Repair-proficient HeLa S3 cells were obtained from the stock of
Lineberger Comprehensive Cancer Center (Chapel Hill, NC). Normal (FS)
fibroblasts from an unaffected donor and XP82SF fibroblasts from a patient
with the skin and central nervous system symptoms and extremely low repair
commonly associated with XPA were established from skin biopsies by J.E.
Cleaver. The normal human fibroblasts (CRL1876), repair-proficient Chinese
hamster ovary (CHO) parental cell line AA8 (CRL1859), and the XP-
G(ERCC5) repair deficient CHO line UV135 (CRL1867) were obtained from
the American Type Culture Collection (Rockville, MD). Lymphoblastoid cell
lines were cultured in RPMI-1640 medium supplemented with 20 mM
glutamine, and 15% fetal calf serum (Gibco-BRL, Gaithersburg, MD). Fibroblast
cell lines were grown in Dulbecco’s modified Eagle’s medium (Gibco-BRL)
containing 40 mM glutamine, 15% fetal calf serum, and antibiotics (penicillin,
streptomycin; Gibco-BRL).
Post-UV cell survival and DNA repair measurement Cell survival was
measured by assessing cell growth in microwell plates following exposure to
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UVC doses of 3–12 J per m2 (Kraemer et al, 1989), and was also quantitated
by labeling wells with [3H]hypoxanthine (0.5 µCi per ml, 9.1 Ci per mmol)
for 2–4 h and extracting incorporated acid-insoluble radioactivity (Cleaver
and Thomas, 1988). The number of repair sites per 107 Daltons generated
intracellularly during 4 h after 13 J per m2 was determined by blocking sites
with inhibitors, followed by size determination in alkaline sucrose gradients
(Cleaver, 1981).
Plasmid post-UV host cell reactivation Post-UV host cell reactivation
was measured using the UV-treated plasmid pRSVcat (Protic-Sabljic and
Kraemer, 1985). The CsCl purified plasmid (0.25 µg) was transfected into
0.15 3 106 fibroblasts using 3 µl Lipofectamine (Gibco-BRL) in a total volume
of 1 ml for 5 h, and the chloramphenicol acetyltransferase activity was measured
after 48 h (Moriwaki et al, 1996). In order to assign the XP22BE fibroblasts to
a specific complementation group a simultaneous cotransfection with 0.25 µg
pXPC3 (containing XPC cDNA; Legerski and Peterson, 1992) in addition to
pRSVcat was performed (Carreau et al, 1995).
In vitro DNA repair assay Double-stranded DNA molecules containing a
centrally located 2-aminobutyl-1,3-propanediol moiety to be used as a substrate
with a cholesterol side chain (Mu et al, 1996) were prepared as described
(Matsunaga et al, 1995) using six partially overlapping oligonucleotides. The
cholesterol-containing oligomer was phosphorylated with [γ-32 p] ATP such
that the 140 bp duplex had 32P label on one strand at the sixth phosphodiester
bond 59 to the 2-aminobutyl-1,3-propanediol-cholesterol lesion. This assay
detects the excised damage-containing DNA fragment resulting from dual
incisions both 59 and 39 to the lesion (Huang et al, 1992; Matsunaga et al, 1995;
Reardon et al, 1997). Cell-free extract preparation, reaction conditions, post-
excision processing of DNA, and quantitation were performed as described
(Reardon et al, 1997).
Northern blotting Northern blotting was performed (Legerski and Peterson,
1992) using total cytoplasmic RNA (Khan et al, 1996). The intensity of the
autoradiographic bands was measured using a laser densitometer (Molecular
Dynamics, Sunnyvale, CA).
Reverse transcriptase-polymerase chain reaction (PCR) and DNA
sequencing Poly A1 containing RNA was separated from the total RNA
using oligo-dT cellulose (Amersham Pharmacia Biotech, Piscataway, NJ). The
first strand cDNA was synthesized utilizing 2 µg poly A1 RNA as described
(Khan et al, 1996), and was utilized to amplify the entire coding region of XPC
gene by nested PCR (Li et al, 1993). High-molecular-weight genomic DNA
was isolated and the region surrounding exon 9 and intron 9 was amplified by
PCR. Sequencing was performed using a Sequenase PCR product sequencing
kit (USB, Cleveland, OH) or by cycle sequencing employing dideoxy terminator
chemistry and an ABI 373A DNA sequencer (P.E. Applied Biosystems, Foster
City, CA).
Microsatellite marker analysis Five microsatellite markers, D3S1515 (1),
D3S1307 (1), D3S1304 (1), D3S1270 (1), and D3S1297 (1), near the XPC
locus on chromosome 3 were selected from a search of GenBank and PCR
amplified using the primer pairs indicated in the GenBank listing. Fragment
sizes were measured on polyacrylamide gels.
DNA sequence information analysis Sequences were scanned with the
donor and acceptor individual information weight matrices and the identified
sites were displayed as described previously (Schneider, 1997a, b).
Amino acid measurements Concentrations of amino acids in plasma, urine,
and cerebro-spinal fluid were determined by ion-exchange chromatography on
a Beckman T300 Amino Acid Analyzer (Beckman Instruments, Spinco Division,
Palo Alto, CA).
RESULTS
Case report A 4 y old boy, XP22BE, with XP (born 7 June, 1991)
of Korean ancestry was referred to NIH because of sun sensitivity,
multiple cutaneous neoplasms, and inability to speak (Fig 1). After a
trip to Florida at age 9 mo his skin darkened without blistering or
other signs of acute sunburn. By 1 y of age he had markedly increased
freckling of his face and hands. He began developing skin cancers
before 3 y. He had one squamous cell carcinoma, five basal cell
carcinomas, one invasive melanoma, two melanoma in situ, and several
other pigmented lesions with marked atypia removed by his local
physicians. He was born with a cleft palate and duplex right kidney.
His height was below the fifth percentile and he had hyperactivity
with delayed motor development and absent speech. Neurologic
Figure 1. Patient XP22BE shows features of XP. The patient, age 4 y,
showing numerous freckle-like pigmented lesions of varying size, shape, and
intensity on sun-exposed portion of the face, lips, and ear. Note sparing of the
chest and shoulders.
examination did not show the neurologic abnormalities typical of XP,
such as diminished deep tendon reflexes, reduced hearing, microce-
phaly, or dilated ventricles of the brain. Instead he had normal reflexes,
autistic features with minimal hearing abnormality, and a normal MRI
of the brain with minimal ventricular prominence. The patient was
adopted and family history is not available.
Hypoglycinemia Plasma glycine levels were consistently dimin-
ished. The mean value was 68 6 14 µM (n 5 6; normal range 125–
318 µM). Conversely, he had mild increases in the plasma levels of
serine, valine, isoleucine, leucine, methionine, and tyrosine. Urine
glycine levels averaged 771 6 380 µmoles per g creatinine (n 5 4;
normal range 1026–4310 µmoles per g creatinine). The glycine level
in cerebro-spinal fluid was 3 µM (normal range 1.9–10.1 µM). Glycine
supplementation at 120 mg per k per d increased the plasma glycine
level into the normal range (166 6 74 µM). (A detailed account of
his clinical and metabolic abnormalities will be presented elsewhere.)
Reduced post-UV survival and DNA repair Post-UV survival
of XP22BE fibroblasts was reduced compared with that of normal
fibroblasts using two different assays. In the growth inhibition assay
following a UV dose of 3 J per m2, the relative survival of XP22BE
cells was 20% of unirradiated cells, whereas that of normal control cells
was 73% (data not shown). In the UV sensitivity assay the D37 (dose
at which 37% of the cells survive) was 5.0 J per m2 for the XP22BE
cells compared with 23–25 J per m2 for normal control cells and 0.8 J
per m2 for XP82SF cells (data not shown). DNA repair as measured
by the number of repair sites accumulated in the presence of polymerase
inhibitors during the 6 h after exposure to 13 J per m2 ultraviolet was
7.5% of normal with XP82SF cells and 16% of normal repair in
XP22BE cells. This is in the range for XP complementation group C
cells (Bootsma et al, 1998).
In vitro and in vivo DNA repair measurements and assignment
to XPC With cell free extracts prepared from repair proficient
human HeLa and CHO AA8 cells, we observed excision of 2.5%–
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Figure 2. In vitro repair and complementation by cell-free extracts and
in vivo complementation with the XPC gene assigning XP22BE cells to
XPC. (A) Qualitative analysis of excision of the 2-aminobutyl-1,3-propanediol-
cholesterol lesion is shown in an autoradiograph of a sequencing gel showing
the excision products resulting from dual incisions during incubation of 8 fmol
substrate DNA with wild-type or mutant cell extracts. Substrate DNA alone is
shown in lane 1 (-CFE); dual incisions by repair-proficient extracts resulted in
the release of 24–32 nucleotide long oligomers shown in lanes 2 and 3 (AA8
and HeLa S3 cells); lack of excision by the extract from XP22BE fibroblasts
(lane 5) is similar to the repair-deficient extracts from XP21RO (XPC) and
UV135 (XPG) fibroblasts (lanes 4 and 9, respectively). In vitro complementation
between XP21RO (XPC) or XP22BE and UV135 (XPG) is shown in lanes 7
and 8, whereas lack of complementation between XP22BE and XP21RO(XPC)
is shown in lane 6. (B) Quantitative analysis of the data shown in (A) and of a
second experiment conducted under similar conditions. Detection of
radioactivity in the 24–32 nucleotide area is markedly reduced in all three
mutant cell lines [XP22BE, XP21RO (XPC), and UV135(XPG)] and is
interpreted as absence of excision repair (i.e., below the level of detection with
this assay) in comparison with the repair proficient HeLa S3 and AA8 lines.
Mixing of extracts from XP22BE or XP21RO (XPC) lines with the UV135(G)
showed increased excision of input DNA, indicating complementation of their
DNA repair defects. In contrast, mixing the XP22BE extract with the XP21RO
(XPC) extract did not increase the excision of input DNA (arrow). This lack of
complementation indicates that XP22BE and XP21RO(XPC) extracts had
similar defects. Thus the XP22BE cells were assigned to XPC. (C) UVC-
treated pRSVcat was either transfected alone (.) or cotransfected with pXPC3
(XPC) (m) or pEBS7 (r) (control) into triplicate cultures of XP22BE primary
fibroblasts. Normal control primary fibroblasts [CRL1876 (d)] were also
transfected without XPC. Each symbol represents the relative chloramphenicol
acetyltransferase activity in an independent transfection compared with the
corresponding control untreated plasmid (Protic-Sabljic and Kraemer, 1985;
Moriwaki et al, 1996). Specific activity with the unirradiated pRSVcat plasmid
in the cell lines used ranged from 0.019 to 0.17 nmol per min per mg protein.
11% of the 2-aminobutyl-1,3-propanediol-cholesterol-A damage
(Fig 2A, lanes 2–3, and Fig 2B). The XP22BE extract had no
detectable excision activity (Fig 2A, lane 5) even after a long exposure
(data not shown). Similarly, extracts prepared from XP21RO (XPC)
and UV135 (XPG CHO) cells showed no excision (Fig 2A, lanes 4
and 9).
In vitro complementation was demonstrated between the extract
Figure 3. Markedly reduced XPC mRNA by northern blotting of
XP22BE cells and analysis and sequencing of cDNA and genomic
DNA. (A) Total RNA (20 µg) was extracted from normal (AG10107), XP21BE
(XPC), and XP22BE cells, separated by electrophoresis and transferred to a
nylon membrane for probing with a 3.5 kb XPC cDNA fragment (XPC). The
relative amount of RNA transferred was monitored by probing with β-actin
cDNA. In comparison with normal cells (lane 1) the XPC message level was
markedly reduced in the XP21BE (XPC) (lane 2) and XP22BE cells (lane 3).
(B) cDNA was prepared by reverse transcriptase-PCR and the XPC region
containing exons 8–11 was amplified by use of PCR and separated by agarose
gel electrophoresis. Lane 1, nucleic acid size markers; lane 2, XP22BE cDNA;
lane 3, normal (AG10107) cDNA. The XP22BE cells show two bands, whereas
only one band is present with the normal cells. (C) Sequence analysis of cDNA
bands from XP22BE cells. The bands from XP22BE cells were extracted from
the agarose gel and dideoxy sequencing was performed using Sequenase as
described in Materials and Methods. Left, the faster migrating band showed
deletion of the entire 161 bases of exon 9. Right, the slower migrating band
had deletion of exon 9 and replacement with a 155 nucleotide insertion (exon
9a, lower case letters). The 11 nucleotides at the 59 end and the 11 nucleotides
from the 39 end of the insertion are shown. (D) Genomic DNA from XP22BE
and normal cells was isolated and amplified by PCR using primers in exon 9
and intron 9. The T in the second position of the 59 splice donor site of intron
9 in the normal cells was replaced by a G in the XP22BE cells.
from XP22BE and UV135 (XPG) (Fig 2A, lane 8) and between the
extract from XP21RO (XPC) and UV135 (XPG) (Fig 2A, lane 7),
indicating that they were not in complementation group G. When the
XP22BE extract was mixed with XP21RO (XPC) cell free extracts,
we failed to detect excision activity with this in vitro system (Fig 2A,
lane 6 and Fig 2B, arrow), thus assigning the XP22BE cells to XPC.
We also conducted in vivo plasmid DNA repair and complementation
studies. The XP22BE fibroblasts showed a reduced post-UV plasmid
host cell reactivation in a range typical for XPC (Fig 2C). This assay
measures the ability of transfected cells to repair damaged plasmid
DNA as reflected in recovery of chloramphenicol acetyltransferase
activity after UVC treatment. Similar results were found with XP22BE
lymphoblasts (data not shown). Cotransfection with the plasmid con-
taining the XPC cDNA (pXPC3) resulted in an enhanced post-UV
chloramphenicol acetyltransferase expression, whereas the cotransfec-
tion with pEBS7 (vector without the XPC gene) did not alter the
post-UV pRSVcat host cell reactivation (Fig 2C). Although plasmid
DNA repair was not fully restored to levels of normal primary
fibroblasts, this clearly assigns XP22BE cells to XPC in vivo (Carreau
et al, 1995).
Reduced XPC transcript by northern blotting We compared
mRNA from the XP22BE lymphoblastoid cell line to mRNA from a
normal donor (AG10107) and from another XPC patient (XP21BE)
by northern blot hybridization (Fig 3A). When the XPC cDNA probe
was used, a single band µ3.8 kb in size was detected in the normal
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control (lane 1), which was consistent with the previously reported
(Legerski and Peterson, 1992) description of XPC mRNA expression.
In contrast, the 3.8 kb transcript was not detectable or was much
reduced in the XP22BE (lane 3) and XP21BE (XPC) (lane 2) cells.
Hybridization of the same membrane with the β-actin cDNA probe
revealed normal levels in all three cell lines, indicating that the low
levels of XPC transcript in the XP22BE or XPC patients was not a
consequence of degradation of RNA samples isolated from these
cell lines.
Multiple XPC mRNA species The entire 3.5 kb coding sequence
of the XPC gene was examined using direct sequencing of PCR-
amplified first strand cDNA generated by use of reverse transcriptase-
PCR. The PCR products showed the expected size except that primer
pairs d1 and d2 resulted in two bands: one of nearly normal size and
a second of shorter size (Fig 3B, C). The shorter band (isoform I) was
missing 161 bases comprising the entire exon 9. The larger band
(isoform III) also had the same deletion of exon 9 but, in addition,
had an insertion of 155 bases (exon 9a) in its place (Fig 3C).
We amplified cDNA using a new primer derived from this 155 base
pair region that was paired with a primer from exon 9. This approach
revealed the presence of a third cDNA species in the XP22BE cells
(isoform II). This cDNA was comprised of XPC sequences including
exon 9 and exon 9a, but in addition also contained a 68 base pair
insertion (exon 9b) between exon 9 and exon 9a. Sequencing of the
remainder of the coding region of the cDNA from XP22BE patient
revealed no other mutations.
The XP22BE lymphoblastoid cell line we used was established by
Epstein–Barr virus transformation of peripheral blood lymphocytes
from the XP22BE patient. To exclude a possible effect of Epstein–
Barr virus transformation, we also analyzed primary fibroblast cultures
established from the XP22BE patient. We found the same mutations
in the cDNA of the fibroblasts of the XP22BE patient, confirming
that these mutations are in his germ line.
An XPC splice donor mutation in genomic DNA The exon/
intron junctions were sequenced for exons 8, 9, and 10 in the normal
and the XP22BE cells. In addition, the entire intron 9 was sequenced
(GenBank accession number AF076952) and found to contain 3862 bp.
We found a T→G mutation in the 12 position of the 59 end of intron
9 (splice donor site of exon 9) in the XP22BE cells (Fig 3D). The
sequences at the intron–exon junctions represent strong donor and
acceptor sites (Fig 4A, B) (Stephens and Schneider, 1992; Schneider,
1997a, b). The genomic DNA PCR products amplified using primer
pairs spanning exons 9 and 10 were found to be digested with Hinc
II, an enzyme that only cuts within the 155 bp inserted sequence
found in cDNA (Fig 4B). The 68 bp insertion (exon 9b in isoform
II) and 155 bp insertion (exon 9a in isoforms II and III) in the cDNA
were found to be part of intron 9 (Fig 4C).
Homozygous microsatellite markers near the XPC locus on
chromosome 3 Because DNA from the parents of XP22BE was
not available, we used microsatellite markers to determine whether the
region containing the XPC gene on chromosome 3 was homozygous or
heterozygous. All the five microsatellite markers we used revealed
homozygosity (data not shown).
Figure 4. Effects of splice donor site mutation in XP22BE cells. (A)
Lister map for exon 9 and 9b donors in XP22BE and normal. The locations
of donor and acceptor sites are shown by sequence walkers below the
corresponding sequence (Schneider, 1997b). In a walker the height of a letter
indicates how strongly conserved a base is in natural splice junction binding
sites (Stephens and Schneider, 1992). The vertical green or red rectangle is at
the zero base of the site and represents a scale extending from 12 bits to –3
bits. The total conservation and location of the zero base are given for each
walker for all sites .2.4 bits, the apparent minimal functional value (Rogan
et al, 1998). The sequences are numbered starting at 1, the first base of intron
9, and marked by an asterisk every five bases. The donor walker at coordinate
1 (underlined) is the normal exon 9 39 end and has a strong value of 9.7 bits.
In XP22BE cells, substituting a G for the T at base 2 (arrow) reduces the
information content of the exon 9 donor site to 1.5 bits (Schneider, 1997b).
This nonfunctional site is indicated by a red rectangle. There is another splice
donor site at 69 (exon 9b) with an information content of 2.8 bits. The acceptor
at 68 has a high probability (0.2) of being a natural site, but its function, if any,
is unknown. (B) Lister map for exon 9a. The strong acceptor at 2224 (11.8
bits) and the medium strength donor at 2380 (5.1 bits) are at the 59 and 39
ends of 155 bp exon 9a, respectively (underlined). (C) Schematic diagram of
splicing pattern in XP22BE cells. The T→G mutation in the splice donor site
of exon 9 in XP22BE results in three different mRNA isoforms: isoform I has
a loss of exon 9; isoform II has an insertion of exons 9b and 9a; isoform III has
a deletion of exon 9 and insertion of exon 9a.
VOL. 111, NO. 5 NOVEMBER 1998 XPC SPLICE MUTATION WITH HYPOGLYCINEMIA 795
DISCUSSION
DNA repair and XPC Cells from XP patients with severe defects
in nucleotide excision repair are hypersensitive to killing by UV and
to induction of mutations in their DNA by UV exposure (Bootsma
et al, 1998). These studies of XP strongly implicate DNA repair in
protection against UV-induced skin cancers (Kraemer et al, 1994). The
XP22BE patient had multiple skin cancers, including melanoma by
age 4 y. The XP22BE cells had characteristic increased sensitivity to
killing by UV, reduced post-UV plasmid host cell reactivation, and
reduced DNA repair. Cell free extracts from lymphoblasts of this
patient did not correct the excision defect in an XPC cell line, and
in vivo complementation of XP22BE fibroblasts with an XPC gene
resulted in an increased plasmid DNA repair capacity in these cells
nearly up to normal levels. These results assign the XP22BE cells to
the complementation group C.
Neurologic abnormalities and hypoglycinemia About 20% of
XP patients show neurologic abnormalities (Kraemer et al, 1987). Their
neurologic abnormalities are characterized by progressive deterioration
and include diminished deep tendon reflexes, reduced hearing, and
dilated ventricles of the brain (Kraemer et al, 1987; Kraemer, 1998).
Most XP patients with neurologic abnormalities are in XP comple-
mentation groups A, B, D, or G (Kraemer et al, 1987; Bootsma et al,
1998; Kraemer, 1998), and have only rarely been reported in group
C (Hananian and Cleaver, 1980). We found normal plasma amino acid
levels in XP patients with neurologic abnormalities in complementation
groups A (one patient), C (one patient), and D (one patient) (K.H.K.,
unpublished). Nine XP patients in complementation groups B, D, and
G (Moriwaki et al, 1996) have been identified with a second clinical
entity: the XP–Cockayne syndrome complex (Robbins, 1988). These
patients have cutaneous abnormalities of XP and neurologic degenera-
tion of Cockayne syndrome (CS) with microcephaly, normal to
increased deep tendon reflexes, pigmentary retinal degeneration, pro-
gressive sensorineural hearing loss, and calcification of basal ganglia.
Pathologically XP/CS patients have the CS type of neurologic changes
(dysmyelinization of the brain), which differ from those in patients
with XP with neurologic abnormalities (primary neuronal degeneration)
(Robbins, 1988).
The XP22BE patient had neurologic abnormalities not usually found
with either XP or CS, including autistic features with normal hearing,
hyperactivity, normal reflexes, and normal MRI without dilated
ventricles or microcephaly. Rather, his neurologic changes may be
related to the substantial and persistent hypoglycinemia. In addition,
oral glycine supplementation appeared to result in improvement of his
marked hyperactivity.
Hyperglycinemia either as a primary entity known as nonketotic
hyperglycinemia (Hamosh et al, 1995) or secondary to organic acido-
pathies (Fenton and Rosenberg, 1995), is associated with neurologic
abnormalities, the former most likely a consequence of the accumulation
of glycine and the latter likely due to the underlying organic acid
disorder. Hypoglycinemia, however, has not been reported. We have
not defined the metabolic defect producing the hypoglycinemia. A
marked decrease in the concentrations of serine and glycine in cerebro-
spinal fluid and in plasma has been reported to be associated with an early
nonspecific mental retardation in 3-phosphoglycerate dehydrogenase
deficiency, an inborn error of serine metabolism (Jaeken et al, 1996);
however, our patient did not have low serine levels. His serine levels
were 194 and 184 µM (normal range 71–181 µM) with corresponding
glycine levels of 69 and 68 µM, respectively (normal range 125–
318 µM), and was 223 µM when glycine supplementation elevated
his glycine to 192 µM.
XPC gene and hypoglycinemia The function of the XPC gene
is still not fully understood, although the protein encoded by this gene
is thought to be involved in repair of damage to bulk (nontranscribed)
DNA (van Hoffen et al, 1995). XPC forms a stable complex with the
human homologs of the yeast Rad23 protein HHR23A and HHR23B
in XPC exon 12 (Masutani et al, 1994; Li et al, 1997), binds the
transcription/repair factor TFIIH (Drapkin et al, 1994) in exon 14
(R.L., unpublished data), and nonspecifically binds with single-stranded
DNA (Reardon et al, 1996). Depending on their location, different
mutations in a related XP gene (XP-D) are associated with at least
three markedly different clinical phenotypes: (i) XP, (ii) XP/CS
complex, and (iii) trichothiodystrophy (sulfur deficient brittle hair and
mental retardation without skin cancer) (Taylor et al, 1997). Although
other patients with XP have not had amino acid abnormalities, it is
possible that the XPC exon 9 splice mutation has resulted in a new
phenotype (XPC with hypoglycinemia), possibly via production of
alternatively spliced forms of the XPC message.
XPC splice donor mutation Mutations in splice sites decrease
recognition of the adjacent exon and consequently inhibit splicing of
the adjacent intron (Talerico and Berget, 1990; Carothers et al, 1993).
We found a splice donor site mutation (T→G) at the 12 position of
the exon 9/intron 9 junction of XPC (Fig 3D). We have analyzed
the effects of the mutation on RNA processing using an information
theory based approach incorporating information weight matrices that
reflect features of nearly 2000 published donor and acceptor sites
(Schneider, 1997b) (Fig 4A). This mutation reduced the value of the
splice donor site information content from 9.7 to 1.5 bits (Schneider,
1997b). Evidence from analysis of many other splice junction mutations
indicates that sites below 2.4 bits are not functional, and often result
in skipping of the preceding exon (Rogan et al, 1998). Thus the T→G
splice donor mutation results in loss of the 161 bp exon 9 (isoform I,
Fig 4C), resulting in a predicted XPC protein truncated at 657 aa. A
2.8 bit donor site is located at base pair 69 in intron 9 (exon 9b donor,
Fig 4A) and is utilized in isoform II (Fig 4C), resulting in an insertion.
The 155 base pair exon 9a is bounded by a strong acceptor of 11.8
bits and a donor of 5.1 bits (Fig 4B). It was found in isoform II along
with the insertion of exon 9b (Fig 4C), resulting in a predicted XPC
protein truncated at 721 aa. Isoform III contains exon 9a in place of
exon 9 (Fig 4C), resulting in an in-frame alteration potentially
producing nearly full-length XPC protein (938 aa rather than 940 aa).
These altered proteins may have biologic activity that ultimately can
also affect the DNA repair pathways as demonstrated for Fanconi
anemia cells (Yamashita et al, 1996).
Nonsense mutations can enhance mRNA decay rate 10- to 20-fold
(Maquat, 1995; Jacobson and Peltz, 1996; Aoufouchi et al, 1996). The
low level of XPC mRNA in XP22BE cells (Fig 3A) is probably a
consequence of the splice site mutation with resulting premature
termination of mRNA translation in isoforms I and II.
A new syndrome? In XP22BE cells five microsatellite markers on
chromosome 3 near the XPC locus revealed homozygosity. Because
we found only one mutation in the XPC cDNA in XP22BE cells,
this is evidence that the XPC gene also is homozygous for the T→G
splice donor mutation. This splice mutation may have also produced
the hypoglycinemia by a presently unknown mechanism. Alternatively,
the hypoglycinemia may be the result of homozygous mutation(s) in
other, unidentified, gene(s). By analogy with the discovery of the XP/
CS complex (Robbins et al, 1974), we cannot be certain that the
hypoglycinemia is caused by the XPC splice mutation until additional
patients are found either with the same XPC mutation or with XP
and hypoglycinemia. In conclusion, the association of an XPC splice
site mutation, unusual neurologic abnormalities (normal reflexes and
normal hearing with autistic features), and hypoglycinemia in XP22BE
patient may represent a new XPC syndrome.
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